| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Chemoprevention Program, American Health Foundation, Valhalla, New York 10595 [C. V. R., C. I., B. S., B. S. R.], and Arthritis and Inflammation Pharmacology Research [P. T. M., J. R. C.], Pharmacia Corporation, St. Louis, Missouri 63137
The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM). iNOS may regulate COX-2 production of proinflammatory prostaglandins, which are known to play a key role in colon tumor development. Experiments were designed to assess the potential chemopreventive properties of highly selective iNOS inhibitors, administered individually and in combination with a selective COX-2 inhibitor, on the development of AOM-induced colonic aberrant crypt foci (ACF). F344 rats were fed experimental diets containing one of the following: 0, 10, 30, or 100 parts/million (ppm) of the selective iNOS inhibitor L-N6-(1-iminoethyl)lysine tetrazole-amide (SC-51); 1800 ppm of the less potent, selective iNOS inhibitor aminoguanidine (AG); 500 ppm of the COX-2 inhibitor celecoxib; 320 ppm of the nonsteroidal anti-inflammatory sulindac (positive control); or 30 ppm of SC-51 with 500 ppm of celecoxib, and 100 ppm of SC-51 with 500 ppm of celecoxib. One and 2 weeks later, rats received s.c. injections of AOM at a dose of 15 mg/kg of body weight. At 17 weeks of age, all rats were sacrificed. Colons were evaluated for ACF, and colonic mucosae were assayed for COX and NOS isoform enzyme activities. Samples of venous blood, collected at various time points, were analyzed for these agents. SC-51, administered alone, demonstrated dose-dependent inhibition of the incidence of colonic ACF. The highest doses of SC-51 (100 ppm) and AG (1800 ppm) significantly suppressed the incidence of colonic ACF (P < 0.01 and < 0.001, respectively) and crypt multiplicity in terms of numbers of aberrant crypts/focus (P < 0.0001). Importantly, the combination of either low or high effective doses of SC-51 (30 or 100 ppm) and celecoxib (500 ppm) suppressed AOM-induced colonic ACF formation (P < 0.05 and < 0.001, respectively) and reduced multiplicity of four or more aberrant crypts/focus (P < 0.0001) to a greater extent than did these agents administered individually. As expected, sulindac inhibited colonic ACF formation (P < 0.001) and reduced the multiplicity of four or more aberrant crypts (P < 0.0001) to 
45%. The enzymatic activities of COX-2 and iNOS were significantly induced in the AOM-treated animals, and administration of the iNOS inhibitors, SC-51 and AG, significantly inhibited the activities of both iNOS and COX-2 in the colonic mucosa. The combined administration of SC-51 and celecoxib inhibited the COX-2 activity to a greater extent than did either of these agents administered alone. These findings support the hypothesis that selective iNOS inhibitors may have chemopreventive properties and that coadministration with a selective COX-2 inhibitor may have additional chemopreventive potential.
This article has been cited by other articles:
|
|
 |
|
  C. V. Rao, V. E. Steele, M. V. Swamy, J. M.R. Patlolla, S. Guruswamy, and L. Kopelovich Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 Rats Cancer Res., October 15, 2009; 69(20): 8175 - 8182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Paul, A. M. Rimando, H. J. Lee, Y. Ji, B. S. Reddy, and N. Suh Anti-inflammatory Action of Pterostilbene Is Mediated through the p38 Mitogen-Activated Protein Kinase Pathway in Colon Cancer Cells Cancer Prevention Research, July 1, 2009; 2(7): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Di Cello, J. Hillion, J. Kowalski, B. M. Ronnett, A. Aderinto, D. L. Huso, and L. M.S. Resar Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Mol. Cancer Ther., July 1, 2008; 7(7): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, M. Gu, and R. Agarwal Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis Cancer Res., March 15, 2008; 68(6): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nowak, K. H. Weylandt, P. Habbel, J. Wang, A. Dignass, J. N. Glickman, and J. X. Kang Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids Carcinogenesis, September 1, 2007; 28(9): 1991 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hagos, R. E. Carroll, T. Kouznetsova, Q. Li, V. Toader, P. A. Fernandez, S. M. Swanson, and G. R.J. Thatcher Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo Mol. Cancer Ther., August 1, 2007; 6(8): 2230 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhang, A. Ma, S. J. Urbanski, and D.-M. McCafferty Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma Carcinogenesis, May 1, 2007; 28(5): 1122 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stempelj, M. Kedinger, L. Augenlicht, and L. Klampfer Essential Role of the JAK/STAT1 Signaling Pathway in the Expression of Inducible Nitric-oxide Synthase in Intestinal Epithelial Cells and Its Regulation by Butyrate J. Biol. Chem., March 30, 2007; 282(13): 9797 - 9804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Suh, S. Paul, X. Hao, B. Simi, H. Xiao, A. M. Rimando, and B. S. Reddy Pterostilbene, an Active Constituent of Blueberries, Suppresses Aberrant Crypt Foci Formation in the Azoxymethane-Induced Colon Carcinogenesis Model in Rats Clin. Cancer Res., January 1, 2007; 13(1): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. K. Glebov, L. M. Rodriguez, P. Soballe, J. DeNobile, J. Cliatt, K. Nakahara, and I. R. Kirsch Gene Expression Patterns Distinguish Colonoscopically Isolated Human Aberrant Crypt Foci from Normal Colonic Mucosa. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2253 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. K. Glebov, L. M. Rodriguez, P. Lynch, S. Patterson, H. Lynch, K. Nakahara, J. Jenkins, J. Cliatt, C.-J. Humbyrd, J. DeNobile, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1382 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vanamala, T. Leonardi, B. S. Patil, S. S. Taddeo, M. E. Murphy, L. M. Pike, R. S. Chapkin, J. R. Lupton, and N. D. Turner Suppression of colon carcinogenesis by bioactive compounds in grapefruit Carcinogenesis, June 1, 2006; 27(6): 1257 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hong, S. Sang, H.-J. Park, S. J. Kwon, N. Suh, M.-T. Huang, C.-T. Ho, and C. S. Yang Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives Carcinogenesis, February 1, 2006; 27(2): 278 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, Y. Yan, J. Li, Q. Ma, G. D. Stoner, J. Ye, and C. Huang Differential requirement of signal pathways for benzo[a]pyrene (B[a]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells Carcinogenesis, June 1, 2005; 26(6): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R K Wali, H K Roy, Y L Kim, Y Liu, J L Koetsier, D P Kunte, M J Goldberg, V Turzhitsky, and V Backman Increased microvascular blood content is an early event in colon carcinogenesis Gut, May 1, 2005; 54(5): 654 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, R. Suzuki, H. Kohno, S. Sugie, M. Takahashi, and K. Wakabayashi Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess {beta}-catenin gene mutations and increases immunoreactivity for {beta}-catenin, cyclooxygenase-2 and inducible nitric oxide synthase Carcinogenesis, January 1, 2005; 26(1): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Dandekar and B. L. Lokeshwar Inhibition of Cyclooxygenase (COX)-2 Expression by Tet-Inducible COX-2 Antisense cDNA in Hormone-Refractory Prostate Cancer Significantly Slows Tumor Growth and Improves Efficacy of Chemotherapeutic Drugs Clin. Cancer Res., December 1, 2004; 10(23): 8037 - 8047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pereira, L. Tao, W. Wang, Y. Li, A. Umar, V. E. Steele, and R. A. Lubet Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-{alpha} gene in rat colon tumors Carcinogenesis, October 1, 2004; 25(10): 1917 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Lind Arginine and Cancer J. Nutr., October 1, 2004; 134(10): 2837S - 2841S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shishodia, D. Koul, and B. B. Aggarwal Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-{kappa}B Activation through Inhibition of Activation of I{kappa}B{alpha} Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of COX-2 Synthesis J. Immunol., August 1, 2004; 173(3): 2011 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shishodia and B. B. Aggarwal Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates Activation of Cigarette Smoke-Induced Nuclear Factor (NF)-{kappa}B by Suppressing Activation of I-{kappa}B {alpha} Kinase in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of Cyclin D1, COX-2, and Matrix Metalloproteinase-9 Cancer Res., July 15, 2004; 64(14): 5004 - 5012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ishimura, S. F. Bronk, and G. J. Gores Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G88 - G95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, R. G. Nines, S. M. Peschke, L. A. Kresty, and G. D. Stoner Chemopreventive Effects of a Selective Nitric Oxide Synthase Inhibitor on Carcinogen-Induced Rat Esophageal Tumorigenesis Cancer Res., May 15, 2004; 64(10): 3714 - 3717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, G. L. Borchert, and J. M. Phang Polyoma Enhancer Activator 3, an Ets Transcription Factor, Mediates the Induction of Cyclooxygenase-2 by Nitric Oxide in Colorectal Cancer Cells J. Biol. Chem., April 30, 2004; 279(18): 18694 - 18700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ikezoe, Y. Yang, D. Heber, H. Taguchi, and H. P. Koeffler PC-SPES: A Potent Inhibitor of Nuclear Factor-{kappa}B Rescues Mice from Lipopolysaccharide-Induced Septic Shock Mol. Pharmacol., December 1, 2003; 64(6): 1521 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dhar, J. M. Brindley, C. Stark, M. L. Citro, L. K. Keefer, and N. H. Colburn Nitric oxide does not mediate but inhibits transformation and tumor phenotype Mol. Cancer Ther., December 1, 2003; 2(12): 1285 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, C. R. Herzog, and C. V. Rao Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53 Cancer Res., September 1, 2003; 63(17): 5239 - 5242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay Is Inducible Nitric Oxide Synthase a Target for Chemoprevention? Mol. Cancer Ther., August 1, 2003; 2(8): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, S.T.F. Chan, and R. Mahendran Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines Carcinogenesis, April 1, 2003; 24(4): 637 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Narayanan, N. K. Narayanan, B. Simi, and B. S. Reddy Modulation of Inducible Nitric Oxide Synthase and Related Proinflammatory Genes by the Omega-3 Fatty Acid Docosahexaenoic Acid in Human Colon Cancer Cells Cancer Res., March 1, 2003; 63(5): 972 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cianchi, C. Cortesini, O. Fantappie, L. Messerini, N. Schiavone, A. Vannacci, S. Nistri, I. Sardi, G. Baroni, C. Marzocca, et al. Inducible Nitric Oxide Synthase Expression in Human Colorectal Cancer: Correlation with Tumor Angiogenesis Am. J. Pathol., March 1, 2003; 162(3): 793 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dong, K. Guda, P. R. Nambiar, A. Rezaie, G. S. Belinsky, G. Lambeau, C. Giardina, and D. W. Rosenberg Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis Carcinogenesis, February 1, 2003; 24(2): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Kisley, B. S. Barrett, A. K. Bauer, L. D. Dwyer-Nield, B. Barthel, A. M. Meyer, D. C. Thompson, and A. M. Malkinson Genetic Ablation of Inducible Nitric Oxide Synthase Decreases Mouse Lung Tumorigenesis Cancer Res., December 1, 2002; 62(23): 6850 - 6856. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
